business
Lucid Diagnostics Q1 Earnings Call Highlights
Key takeaways
- Lucid Diagnostics Q1 Earnings Call Highlights Market Beat Fri, May 15, 2026 at 12:10 AM GMT+7 7 min read LUCD LCID Key Points Interested in Lucid Diagnostics Inc.?
- Lucid Diagnostics reported Q1 2026 Eso Guard test volume of 3,177 and revenue of $1.3 million, with volume still above its pre-Medicare target range despite a sequential decline from Q4.
- Management said the company remains highly focused on a Medicare local coverage determination, calling it the key near-term catalyst and expecting a positive outcome despite delays in the process.
Lucid Diagnostics Q1 Earnings Call Highlights Market Beat Fri, May 15, 2026 at 12:10 AM GMT+7 7 min read LUCD LCID Key Points Interested in Lucid Diagnostics Inc.? Here are five stocks we like better.
Lucid Diagnostics reported Q1 2026 Eso Guard test volume of 3,177 and revenue of $1.3 million, with volume still above its pre-Medicare target range despite a sequential decline from Q4.
Management said the company remains highly focused on a Medicare local coverage determination, calling it the key near-term catalyst and expecting a positive outcome despite delays in the process.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
Earnings call transcript: Extendicare Inc. Q1 2026 earnings beat estimates
Investing.com
Earnings call transcript: Cellebrite Q1 2026 earnings beat estimates
Investing.com
Earnings call transcript: Definity Financial exceeds Q1 2026 expectations
Investing.com
Earnings call transcript: WhiteFiber Q1 2026 sees significant EPS miss
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop